NMPA Approves the PD-1 agonist GenSci120 for Clinical Trials Commencement

On January 15, 2025, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) received approval from the National Medical Products Administration (NMPA) for its independently developed humanized antibody, the PD-1 agonist GenSci120, to proceed with clinical trials including adult systemic lupus erythematosus and adult primary Sjögren’s syndrome. 

Globally, over a dozen PD-1 agonists are in development, with most still in preclinical stages. The preclinical studies have demonstrated that GenSci120 injection offers a relatively specific targeted immunosuppressive effect, highlighting its potential as a therapeutic option for autoimmune diseases.

Dr. John Xu, GenSci's Executive Vice President of Immunology and Oncology Drug Development and a key inventor of GenSci120, stated: "Preclinical data shows GenSci120’s Best-in-Class potential, giving us confidence to explore its use across multiple indications."